Showing results (881-890 of 918) with videos related to
Sort By:
Pageof 92
Molecular Cancer Therapeutics|March 5, 2016
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Maria Menichincheri, Patrizia Banfi, et al.Clinical Immunology (Orlando, Fla.)|December 4, 2019
Reduced PD-1 expression on circulating follicular and conventional FOXP3+ Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk childrenAndrea Vecchione, Roberta Di Fonte, Jolanda Gerosa, et al.International Journal of Molecular Sciences|May 7, 2025
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular CarcinomaIlaria Leoni, Giuseppe Galvani, Elisa Monti, et al.Lancet (London, England)|November 18, 2021
Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USASaad B Omer, Regina M Benjamin, Noel T Brewer, et al.Bioorganic & Medicinal Chemistry|July 11, 2014
Pyrrole-3-carboxamides as potent and selective JAK2 inhibitorsMaria Gabriella Brasca, Marcella Nesi, Nilla Avanzi, et al.Molecular Oncology|June 26, 2014
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Roberta Bosotti, Andrea Lombardi Borgia, et al.Journal of Medicinal Chemistry|July 30, 2015
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer TherapyGianluca Papeo, Helena Posteri, Daniela Borghi, et al.Diabetes|October 8, 2021
Reduced Follicular Regulatory T Cells in Spleen and Pancreatic Lymph Nodes of Patients With Type 1 DiabetesAndrea Vecchione, Tatiana Jofra, Jolanda Gerosa, et al.Science Advances|August 25, 2023
Exposure of volunteers to microgravity by dry immersion bed over 21 days results in gene expression changes and adaptation of T cellsCarlos J Gallardo-Dodd, Christian Oertlin, Julien Record, et al.Journal of Medicinal Chemistry|March 23, 2016
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitorMaria Menichincheri, Elena Ardini, Paola Magnaghi, et al.Pageof 92